| P2093 | author name string | Michael Böhm | |
| | Christian Werner | |
| | Janine Pöss | |
| P2860 | cites work | ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] | Q22306349 |
| | The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 |
| | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| | Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 |
| | Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. | Q31383623 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more | Q33876182 |
| | Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan | Q34150300 |
| | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 |
| | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 |
| | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 |
| | Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. | Q34369863 |
| | Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction | Q34427866 |
| | Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? | Q34443692 |
| | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 |
| | Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 |
| | Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 |
| | A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein | Q34578959 |
| | Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 |
| | Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 |
| | 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q34636529 |
| | Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 |
| | Rosuvastatin in older patients with systolic heart failure | Q34710349 |
| | A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group | Q34718800 |
| | Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 |
| | Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension | Q36088984 |
| | Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? | Q36443390 |
| | Activation of neurohumoral systems following acute myocardial infarction. | Q36535717 |
| | Renin-angiotensin system and cardiovascular risk | Q36784673 |
| | Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness | Q36813497 |
| | Rationale for double renin-angiotensin-aldosterone system blockade | Q36897549 |
| | Angiotensin-converting-enzyme inhibition in stable coronary artery disease | Q36915313 |
| | Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 |
| | Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi | Q37125268 |
| | Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. | Q37344514 |
| | Review: renal protection by inhibition of the renin-angiotensin-aldosterone system | Q37415058 |
| | Managing cardiovascular and renal risk: the potential of direct renin inhibition | Q37510348 |
| | ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial | Q37563491 |
| | Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement | Q37678374 |
| | Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study | Q38397719 |
| | Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 |
| | Prognostic significance of endothelial dysfunction in hypertensive patients | Q40697812 |
| | Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 |
| | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial | Q43252263 |
| | Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. | Q43256623 |
| | Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 |
| | Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Asse | Q43273403 |
| | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect | Q44090671 |
| | Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study | Q44357140 |
| | Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study | Q44485270 |
| | Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure | Q44925680 |
| | Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial | Q44933488 |
| | Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program | Q45091727 |
| | Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). | Q45940726 |
| | Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program | Q46083552 |
| | Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction | Q46135227 |
| | Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 |
| | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). | Q46340479 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 |
| | Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition | Q46842033 |
| | The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). | Q46951742 |
| | Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 |
| | Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial | Q61456626 |
| | Neuroendocrine changes in acute myocardial infarction | Q70242408 |
| | Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation | Q70986050 |
| | Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators | Q72232746 |
| | Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall | Q72413333 |
| | Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome | Q73395324 |
| | The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis | Q77531127 |
| | The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation | Q77559165 |
| | Angiotensin in the kidney: a key to understanding hypertension? | Q79451343 |
| | Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? | Q79760092 |
| | Networking between systemic angiotensin II and cardiac mineralocorticoid receptors | Q79780285 |
| | Effect of spironolactone on blood pressure in subjects with resistant hypertension | Q79798622 |
| | The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren | Q80972193 |
| | Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 |
| | 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve | Q83631957 |
| | Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis | Q94691477 |
| P433 | issue | 10 | |
| P304 | page(s) | 1215-1230 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? | |
| P478 | volume | 70 | |